Euronext Core Europe 30 ESG EW Decrement 5 NR (CESG3)

DCVax-L is a massively expensive treatment competing with an inexpensive generic treatment. NICE wouldn't fund CAR-T for years and then only with a limited quota each year. NICE is going to chock on the cost of DCVax-L as they have limited budget.

$BTC.X Nice rebound!!! Now taking sister BIO Crypto surges to $23 great AI developments! like RAVE did in April.. #1 next runner-up! Congrats! BIO $23

It's not the oil as much as what comes after the oil. Refined. Not to mention pipelines.

https://media.stocktwits-cdn.com/api/3/media/13018367/default.webp
https://on24static.akamaized.net/event/53/40/40/0/rt/1/documents/resourceList1781697907207/ampriusintroductionq220261781697907207.pdf

https://www.youtube.com/watch?v=iL4fxqAk_08

https://www.bleepingcomputer.com/news/security/fortibleed-leak-exposes-fortinet-vpn-credentials-for-73-000-devices/amp/

Make the smart move and switch to Wave!!!!

Fingers crossed and keeping buying little by little down here

https://media.stocktwits-cdn.com/api/3/media/13018367/default.webp
https://on24static.akamaized.net/event/53/40/40/0/rt/1/documents/resourceList1781697907207/ampriusintroductionq220261781697907207.pdf

https://www.youtube.com/watch?v=iL4fxqAk_08

But Yet NWBO has NOT filed for approval with the FDA and files in UK with only 1/10th the market potential. Prove otherwise.

GL.

Latest News & Updates
BusinessZincInvestmentSilverMiningCopperGold
March 26, 2026
North Bay Resources Announces Acquisition of Bendito Resources

for those folks hard to read in English

Let the party countdown begin
https://www.cnn.com/2026/06/17/world/live-news/iran-war-g7-summit

Agreed. I wouldn’t be surprising if the stock actually ends up lower on the day of UK news than the 100% jump that many are expecting. The bag holders are trapped and are hoping for a miracle so they can get out, which is unlikely given how long this has taken.

It’s clear there will

Om, >> TACO

https://investorshub.advfn.com/uimage/uploads/2026/6/17/gccx[IMG_4508.jpeg
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrn/amarin/valuation

Add Bessent, Mnuchin, Calabria, Yellen and (maybe Pulte) also to the list. After all they did not write books on restructuring or have best sellers in Amazon. They are JAG (just another government employee)

ReList UpList
Whatdawe want?
ReList UpList - When? By Friday Open
Make It Happen - Sing It
ReList UpList
Whatdawe want?
ReList UpList - When? By Friday Open
Sing It

Nope. You can submit NICE reimbursement evidence before MHRA approval to align reimbursement decision closely on the heels of MHRA approval, but continue to BS. Just like your naked short theory!

JAMA or even Nature does not make regulatory decisions. If they did, then there would be

It's always a scam with Carnes and his buddies. Lenny Greene of INKW and Larry Powalisz of ADIA are his partners in crime

Here's the latest for those wondering on the legal....
GH words
Vechery is Amended with a status hearing on July 1, and probably to decision of the court by November.

(Alfred) Hildebrand - waiting to see if the Sheriff finds in his two accounts according to an Asset Se

https://ibmi.taiwan-healthcare.org/en/news_detail.php?REFDOCTYPID=0o4dd9ctwhtyumw0&REFDOCID=0tgmqxq9rhmy2p50&PageNO=0

#1.2 SPX Cycles Expanded Report: Current Cycles Between Cycles (CCBC) is -46 (Extreme bearish). Extreme Overdue: 60 min (60-S-1, 60-1) Daily (D-S-1) Weekly (W-1). Tomorrow another chance for a Daily Bear Cycle D-S-1 (Extreme Overdue) at the close.

https://investorshub.advfn.com/uimag

https://research.patient.info/research/trials/atherosclerotic-cardiovascular-disease-w-isrctn64669648

#1.2 SPX Cycles Expanded Report: Current Cycles Between Cycles (CCBC) is -46 (Extreme bearish). Extreme Overdue: 60 min (60-S-1, 60-1) Daily (D-S-1) Weekly (W-1). Tomorrow another chance for a Daily Bear Cycle D-S-1 (Extreme Overdue) at the close.

https://investorshub.advfn.com/uimag

Posted on behalf of Luca Mining Corp. - Luca continues to show what an operational turnaround looks like in practice.

Q1 2026:

• Revenue +40% to $57.6M
• EBITDA +160% to $19.7M
• Adj. EBITDA +99% to $25.4M
• Operating cash flow: $21.6M
• Cash

People on the VMHG and NMHI boards are looking for you.